NORRSKEN INITIATIVES

The Norrsken initiatives combine high risk with high impact

We believe this is unexplored territory in a world where non-profits avoid financial risks, and venture capitalists focus only on financial return

29k

Initiative 001

Increasing our speed can never compensate for heading in the wrong direction. We believe a better society comes from wiser decisions and actions. Therefore 29k aims to democratize personal growth by combining the best empirical experience, research and tech.

READ MORE

IMPACT WEEK

Initiative 002

On September 16th–19th 2019 Stockholm became the world’s center for startups that make the world a better place, giving them the attention they truly deserve.

A week filled with intellectual conversations and meaningful meetings that gathers CEOs, policymakers, top talents, entrepreneurs, and startups under the same roof with the purpose of inspiring everyone to take action and be a driving force for change.

READ MORE

KLARITY

Initiative 003

Klarity engages citizens in exposing everyday corruption. 1 out of 4 people around the world have to pay bribes to access public services. Klarity aims to give them a voice.

READ MORE

ACTION AGAINST CORONA

Initiative 004

The coronavirus disease COVID-19 is a global pandemic. We are experiencing the worst public health crisis in a generation. Norrsken Foundation and Sweden’s leading business newspaper Dagens Industri has launched a joint venture to support initiatives that can improve the situation for the sick, for the healthcare system, or for the billions of people affected.

Through actionagainstcorona.org Norrsken connects initiatives with financial support as well as partners, authorities and volunteers. Grants and investments come from the Norrsken Foundation and from Norrsken VC, which invests in companies that solve social problems.

READ MORE

OSMOND LABS

Initiative 005

More than 260 million people worldwide suffer from depression, according to WHO. Osmond Labs was founded in 2020 and is a pharmaceutical company focused on conducting and supporting clinical research on the treatment potential of psychedelic substances.

The company’s long-term goal is to develop and provide new, safe and cost-effective treatment options, based on psychedelic substances, for a broad spectrum of mental health disorders. The first project is a clinical trial at the Karolinska institute investigating psilocybin-assisted psychotherapy for depression.

Osmond Labs is wholly owned by Osmond Foundation, and financed through a donation from Norrsken Foundation. Future revenue will be reinvested in research into and education of new treatment methods involving psychedelic substances.

READ MORE
CONTACT
MENU